SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-22-001621
Filing Date
2022-01-05
Accepted
2022-01-05 18:53:20
Documents
1
Period of Report
2022-01-05

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm221868-4_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm221868-4_4seq1.xml 4 3709
  Complete submission text file 0001104659-22-001621.txt   5156
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Issuer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O TITAN PHARMACEUTICALS INC 400 OYSTER POINT BLVD S SAN FRANCISCO CA 94080
Business Address
MACFARLANE M DAVID (Reporting) CIK: 0001182314 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-13341 | Film No.: 22512981